Raymond James Financial Inc Galectin Therapeutics Inc Transaction History
Raymond James Financial Inc
- $264 Billion
- Q4 2024
A detailed history of Raymond James Financial Inc transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Raymond James Financial Inc holds 11,550 shares of GALT stock, worth $15,015. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,550Holding current value
$15,015% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GALT
# of Institutions
95Shares Held
9.98MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$2.77 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.03 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.54 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$1.12 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$628,2430.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $77.3M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...